Can DNA ‘Witness’ Race?: Forensic Uses of an Imperfect Ancestry Testing Technology
Fullwiely D. Can DNA ‘Witness’ Race?: Forensic Uses of an Imperfect Ancestry Testing Technology. In Krimsky S, Sloan K Race and the Genetic Revolution: Science, Myth, and Culture New York: Columbia University Press; 2011. pp. 116-26. Publisher's Version
The Enculturated Gene: Sickle Cell Health Politics and Biological Difference in West Africa
Fullwiley D. The Enculturated Gene: Sickle Cell Health Politics and Biological Difference in West Africa. Princeton, NJ: Princeton University Press; 2011. Publisher's Version
Fullwiley D. Revaluating Genetic Causation: Biology, Economy, and Kinship in Dakar, Senegal. American Ethnologist [Internet]. 2010;37(4):638-735. Publisher's VersionAbstract
In this article, I call for enlarging the conceptual terrain for viewing local biological expressions of illness. To date, a specific DNA sequence pattern, called “the Senegalese sickle cell haplotype,” has enjoyed extraordinary purchase on explanations for why Senegalese people may live with a “milder” form of sickle cell anemia when compared with other African populations. I argue, however, that “mild sickle cell” in Senegal emerges as a lived construct through a constitutive bond of biology, economy, and kinship. I show how patients’ enactments of biological difference are situated within larger informal economies and North–South donor priorities for health. In the absence of state funding to address patients’ needs, Senegalese sicklers create networks of care, health, and normalcy by drawing on Wolof idioms of “shared blood” that come to life in ways beyond metaphor. Their biosocial kinships result in therapeutic economies that restructure valuations of sickle cell despite serious medical constraints in this global context.
Fullwiley D. Out From Under the Skin: Disease Etiology, Biology, and Society: A Commentary on Robert Aronowitz. Social Science & Medicine. 2008;67(1):14-17.
Fullwiley D, Bolnick DA, Marks J, Reverby SM, Kahn J, TallBear K, Reardon J, Cooper RS, Duster T, Fujimura JH, et al. The Legitimacy of Genetic Ancestry Tests. Science. 2008;319:1039-1040.
"The Molecularization of Race and Institutions of Difference: Pharmacy and Public Science after the Genome"
Fullwiley D. "The Molecularization of Race and Institutions of Difference: Pharmacy and Public Science after the Genome". In Koenig BA, Lee SS, Richardson S Revisiting Race in a Genomic Age (Studies in Medical Anthropology) New Brunswick, NJ: Rutgers University Press; 2008. pp. 149-171. Publisher's Version
Fullwiley D. The Biologistical Construction of Race: `Admixture' Technology and the New Genetic Medicine. Social Studies of Science [Internet]. 2008;38(5):695-735. Publisher's VersionAbstract
The Biologistical Construction of Race `Admixture' Technology and the New Genetic Medicine Duana Fullwiley1 + Author Affiliations 1Department of Anthropology, 33 Kirkland Street, William James Hall, Cambridge, MA 02138, USA, Abstract This paper presents an ethnographic case study of the use of race in two interconnected laboratories of medical genetics. Specifically, it examines how researchers committed to reducing health disparities in Latinos with asthma advance hypotheses and structure research to show that relative frequencies of genetic markers characterize commonly understood groupings of race. They do this first by unapologetically advancing the idea that peoples whom they take to be of the `Old World', or `Africans', `Europeans', `East Asians', and `Native Americans', can serve as putatively pure reference populations against which genetic risk for common diseases such as asthma can be calculated for those in the `New World'. Technologically, they deploy a tool called ancestry informative markers (AIMs), which are a collection of genetic sequence variants said to differ in present-day West Africans, East Asians, Europeans, and (ideally Pre-Columbian) Native Americans. I argue that this technology, compelling as it may be to a range of actors who span the political spectrum, is, at base, designed to bring about a correspondence of familiar ideas of race and supposed socially neutral DNA. This correspondence happens, in part, as the scientists in question often bracket the environment while privileging racialized genetic variance as the primary source of health disparities for common disease, in this case between Mexicans and Puerto Ricans with asthma. With their various collaborators, these scientists represent a growing movement within medical genetics to re-consider race and `racial admixture' as biogenetically valid points of departure. Furthermore, many actors at the center of this ethnography focus on race as a function of their personal identity politics as scientists of color. This to say, they are driven not by racist notions of human difference, but by a commitment to reduce health disparities and to include `their' communities in what they describe as the `genetic revolution'.
Fullwiley D. The Molecularization of Race: Institutionalizing Racial Difference in Pharmacogenetics Practice. Science as Culture. 2007;16(1):1-30.
Fullwiley D. Race and Genetics: Attempts to Define the Relationship. BioSocieties [Internet]. 2007;2(2):221-237. Publisher's VersionAbstract
Abstract Many researchers working in the field of human genetics in the United States have been caught between two seemingly competing messages with regard to racial categories and genetic difference. As the human genome was mapped in 2000, Francis Collins, the head of the publicly funded project, together with his privately funded rival, announced that humans were 99.9 percent the same at the level of their genome. That same year, the National Institutes of Health (NIH) began a research program on pharmacogenetics that would exploit the .01 percent of human genetic difference, increasingly understood in racial terms, to advance the field of pharmacy. First, this article addresses Collins’ summary of what he called the ‘vigorous debate’ on the relationship between race and genetics in the open-access special issue of Nature Genetics entitled ‘Genetics for the Human Race’ in 2004. Second, it examines the most vexed (if not always openly stated) issue at stake in the debate: that many geneticists today work with the assumption that human biology differs by race as it is conceived through American census categories. It then presents interviews with researchers in two collaborating US laboratories who collect and organize DNA by American notions of ‘race/ethnicity’ and assume that US race categories of classification largely traduce human biogenetic difference. It concludes that race is a practical and conceptual tool whose utility and function is often taken for granted rather than rigorously assessed and that ‘rational medicine’ cannot precede a rational approach to addressing the nature of racial disparities, difference and inequality in health and society more broadly.
Braun L, Fullwiley D,, Hammonds EM, Nelson A, Quivers W, Reverby SM, Shields AE. Racial Categories in Medical Practice: How Useful Are They?. Public Library of Science Medicine (PLoS Medicine) [Internet]. 2007;4(9):1423-1428. Publisher's Version pmed.0040271.pdf
Bolnick DA, Fullwiley D, Duster T, Cooper RS, Fujimura JH, Kahn J, Kaufman JS, Marks J, Morning A, Nelson A, et al. The Science and Business of Ancestry Testing. Science [Internet]. 2007;318(5849):399-400. Publisher's Version science-2007-bolnick-399-400.pdf
Fullwiley D. Biosocial Suffering: Order and Illness in Urban West Africa. BioSocieties [Internet]. 2006;1(4):421-438. Publisher's VersionAbstract
Biosocial Suffering: Order and Illness in Urban West Africa Duana Fullwiley Abstract In the medical literature in the United States and France, sickle cell trait (HbAS) is generally described as a benign condition. Curiously, however, people in Dakar, Senegal, and women in particular, complain of symptoms attributed to this trait, which most doctors in this part of West Africa diagnose as a moderate form of sickle cell anemia—a professional tendency that is now beginning to change. This article draws on ethnographic materials to understand Senegalese sickle cell trait suffering as an instance of social suffering mediated not only through cultural and biological forms, but also through cultural and biological |[lsquo]|options|[rsquo]| to be sick. It examines the interplay of social distresses caused by sickle cell trait, and disease, diagnoses. It concludes that suffering attributed to sickle cell trait consists of a complex nexus marked by economic privations, social practices that are specifically gendered as female, religious fatalism and various ecological and environmental stressors. Theoretically, this article joins the concept of social suffering to that of biosociality. The resultant assemblage is |[lsquo]|biosocial suffering|[rsquo]| whereby women with sickle cell trait articulate and manifest social and physical pains through the biological entity of this recessive allele. BioSocieties (2006) 1, 421–438. doi:10.1017/S1745855206004042 To read this article in full you may need to log in, make a payment or gain access through a site license .